Navigation Links
Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
Date:3/7/2008

Two major defendants - AstraZeneca and Bristol-Myers Squib - not part of

settlement

BOSTON, March 7 /PRNewswire/ -- Today eleven major pharmaceutical companies, including Abbott Laboratories (NYSE: ABT) and Watson Pharmaceuticals (NYSE: WPI), agreed to a $125 million nationwide settlement in the average wholesale price (AWP) litigation filed in 2002 by consumers and insurance companies, which claimed the defendants intentionally inflated reports of the average wholesale prices on certain prescription drugs.

The published AWP is used to set the price that consumers making Medicare Part B co-payments and Medicare pay for the drug, as well as insurance companies and other third-party payors. The lawsuit contends that consumers and third-party payors paid more than they should because of the drug companies' false AWP reporting.

Seattle-based Hagens Berman, co-lead counsel in the case, announced today's settlement which includes branded and generic drugs used primarily in the treatment of cancer, HIV and other serious illnesses. Under the terms of the settlement 82.5 percent of the settlement fund is designated for third-party payors' claims and the remaining 17.5 percent is designated for consumer claims.

"This is a very good settlement for third-party payors and consumers," said Steve Berman, Hagens Berman managing partner. "The battle isn't over yet, but every settlement signifies that our claims are just and these drug companies have many years of damage to repay to drug purchasers."

The defendants included in today's settlement are Abbott Laboratories, Amgen Inc., Aventis Pharmaceuticals Inc., Hoechst Marion Roussel, Baxter Healthcare Corp., Baxter International Inc., Bayer Corporation, Dey, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Immunex Corporation, Pharmacia Corporation, Pharmacia & Upjohn LLC, Sicor, Inc., Gensia, Inc., Gensia Sicor Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc., and ZLB Behring, L.L.C.

Drugs covered in this settlement include Aranesp, Epogen, Neupogen, Neulasta, Anzemet, Ferrlecit and Infed.

Medicare Part B recipients eligible to participate in the settlement will receive a mailing outlining claim procedures. The class includes anyone who reimbursed any portion of an insured's Medicare Part B co-payment between Jan. 1, 1991 through Jan. 1, 2005 or those who made reimbursements outside of Medicare Part B for any of the named drugs from Jan 1, 1991 through March 1, 2008. The court will hold a final hearing to approve all settlement details.

Other settlements in the AWP case came in August of 2006 when GlaxoSmithKline agreed to a nationwide $70 million settlement and May of 2007 when AstraZeneca agreed to a $24 million settlement to Medicare Part B Zoladex users nationwide. After a trial, the court in November 2007 ordered AstraZeneca and Bristol-Myers Squibb to pay nearly $14 million to insurance companies and consumers in Massachusetts for the companies' roles in unfair trade practices.

The court is expected to set a trial date for remaining claims against AstraZeneca and BMS on behalf of insurance companies and consumers outside of Massachusetts.

About Hagens Berman

Hagens Berman, formerly Hagens Berman Sobol Shapiro, is based in Seattle with offices in Chicago, Cambridge, Los Angeles, Phoenix and San Francisco. Since 1993, it has developed a nationally recognized practice in class-action and complex litigation. Among recent successes, HBSS has negotiated a $300 million settlement in the DRAM memory antitrust litigation; a $340 million recovery on behalf of Enron employees; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co-counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS served as counsel in a $850 million Washington Public Power Supply settlement and represented Washington and 12 other states against the tobacco industry that resulted in the largest settlement in history. For a complete listing of HBSS cases, visit http://www.hbsslaw.com.

CONTACTS:

Steve Berman (206) 623-7292

Hagens Berman

steve@hbsslaw.com

Mark Firmani (206) 443-9357

Firmani + Associates Inc.

Mark@firmani.com


'/>"/>
SOURCE Hagens Berman
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
2. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
3. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
4. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
5. Anatomist Dr. Gunther von Hagens Clarifies: Plastinates Not For Sale
6. Eleven Florida Nonprofit Organizations to Receive Grants Totaling Nearly $1 Million From The Blue Foundation
7. Time Domain Adds Eleven Partners to its Channel Reseller Network of PLUS(TM) Ultra Wideband Solutions Providers
8. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
9. Nine Miami Defendants in Strike Force Cases Sentenced for $56.5 Million in Medicare Fraud
10. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
11. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... 23, 2017 , ... Corra Group is now offering exclusively ... Verisys through its FACIS and other services maintains the largest healthcare database ... are delighted to be able to offer these various products to our healthcare ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April ... , How will the new EU MDR language change the way manufacturers ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Wounded Woman ... “Wounded Woman Be Ye Healed-Passing On A Legacy” is the creation of published author, ... founder of Comfortbearers grief ministry. She has been happily married to her husband, ...
(Date:3/23/2017)... ... ... and strong explanation of the God’s love. “More Corruption” is the creation of published author, ... write a book about Him. , She says, “I’m fed up with mortals misjudging me ... God. They have not walked in my shoes and I know they never could for ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... YORK , March 23, 2017 ... sample preparation market is expected to reach USD 7.2 billion ... of 7.1%. Sample preparation is a procedure in which a ... crucial step in most analytical procedures since the methods are ... preparation is one of the most shared procedures in the ...
(Date:3/23/2017)... March 23, 2017  Drug diversion is a ... and deadly overdoses. A new oral fluid monitoring ... www.cordantsolutions.com , reports more detailed and actionable information ... potentially improve therapy adherence, patient safety, and help ... Comprehensive Oral fluid Rx Evaluation (CORE) system is ...
(Date:3/23/2017)... March 23, 2017  The goal of the ... identify and track prescription drugs as they are distributed ... response to requirements from US FDA to better protect ... dangerous medicines. Blockchain startup Chronicled, which ... chips and blockchain technology and recently raised $6.25M, and ...
Breaking Medicine Technology: